Vesugen

What it is

Vesugen is the blood-vessel member of the Khavinson bioregulator family, run by people in their fifties and up who want to do something for circulation and vessel aging. It is a long-game bet on the cells lining your vessels, not a treatment, and you should not expect to feel it.

The Vesugen user is already into the bioregulators, has probably run Epitalon, and wants the vessel one: a family history of stroke or heart disease, cold hands and feet, or a general interest in aging well. It is a three-amino-acid fragment (Lys-Glu-Asp) that the St. Petersburg group assigns to the endothelium, the single-cell lining of every blood vessel, the way Cardiogen is assigned to heart muscle and Cartalax to cartilage. It is not a blood-pressure drug, not a blood thinner, and not for anyone with a diagnosed vascular problem looking for relief.

You will not feel this. There is no energy, no warmth in the hands, no number on a cuff that moves in a way you can attribute to it. The idea is that short peptides nudge which genes the vessel-lining cells read, which is invisible day to day. Some users report better memory and attention, which comes from small Russian studies in elderly patients and is the only human claim with any data behind it. If you want something measurable for circulation, a walking habit, blood-pressure control and a statin conversation do more than any bioregulator.

Our tiers run 500 mcg to 2 mg subQ once a day, with 1 mg the usual pick, for 8 to 12 weeks and then 2 to 4 weeks off. The classic Khavinson pattern is shorter and sparser: a 10 to 20 day course repeated two or three times a year, with a few months between, and many people run it that way instead. Nothing suggests it wears off, so either way the break is caution, not a reset. The 20 mg vial in 2 ml gives 10 mg per ml, so 500 mcg is 5 units, 1 mg is 10 units and 2 mg is 20, and the vial is 20 days at 1 mg: exactly one 20-day course, inside the 3 to 4 weeks a mixed vial keeps, while our 8 to 12 week run takes three to five vials. Often stacked with Cardiogen and Epitalon; do that and you will never know which one did anything.

We grade it animal 1, human 1, which is low: cell and animal work from one research network on endothelial cell turnover, endothelin and SIRT-1 signaling, plus small Russian clinical reports in elderly patients. Nothing replicated in the West and no outcome data on actual vascular events. Plausible mechanism, tiny doses, essentially no proof.

If you have a real vascular diagnosis, your medications and your doctor are the plan and this is noise. If the memory reports are what draw you, Pinealon is the family's brain peptide and has more human work of its own; if it is the family in general, Epitalon has the deeper literature. Skip Vesugen if you have had cancer, since its main lab finding is a rise in a cell-growth marker. Try the 20-day course before committing to the three-to-five-vial long run.

What people use it for

Safety, in brief

The full picture — stop signs and who should talk to a doctor first — is on the dosing guide.

Sources

The labels and studies behind this page. Each link opens the original on PubMed, DailyMed or ClinicalTrials.gov.

1. Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during agingKhavinson et al., Adv Gerontol 2014 · Study
2. Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosisKozlov et al., Adv Gerontol 2016 · Study
3. Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's DiseaseKhavinson et al., Bull Exp Biol Med 2021 · Review
4. Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's DiseaseKhavinson et al., Pharmaceuticals (Basel) 2021 · Study